M
Malcolm R Ranson
Researcher at University of Manchester
Publications - 195
Citations - 15315
Malcolm R Ranson is an academic researcher from University of Manchester. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 57, co-authored 195 publications receiving 14150 citations. Previous affiliations of Malcolm R Ranson include Manchester Academic Health Science Centre & National Health Service.
Papers
More filters
Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study.
Gordon C Jayson,C Mulatero,Malcolm R Ranson,Jamal Zweit,D.L. Hastings,Peter J Julyan,Jeremy A L Lawrance,Alan T McGown,A. Jackson,Hamied A. Haroon,L Hakannson,John Wagstaff,Gerard Groenewegen,FF Lehmann,D. Levitt,T. Tang,H. Zweirzina +16 more
Journal Article
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
TL;DR: Gemcitabine has a role in the palliative treatment of patients with advanced non-small cell lung cancer and provides some survival benefit, but also reduces tumor-related symptoms and improves the performance status of patients receiving chemotherapy.
Journal ArticleDOI
Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer
Emma Dean,Jeffrey Cummings,Anne Roulston,Mark Berger,Malcolm R Ranson,Fiona H Blackhall,Caroline Dive +6 more
TL;DR: The preclinical data and the absence of a peak in circulating caspase-cleaved CK18 in trial patients suggest suboptimal timing of blood sampling, which will need refinement in future trials incorporating obatoclax.
Journal ArticleDOI
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B. Milojkovic Kerklaan,Sarah Slater,M Flynn,Alastair Greystoke,Petronella O. Witteveen,M Megui-Roelvink,F. Y.F.L. de Vos,Emma Dean,Larisa Reyderman,L Ottesen,Malcolm R Ranson,Martijn P. Lolkema,Martijn P. Lolkema,Ruth Plummer,Rebecca Kristeleit,T.R.J. Evans,Jan H.M. Schellens,Jan H.M. Schellens +17 more
TL;DR: Treatment with E7820 is safe and tolerable with 2/3 of patients at MTD having SD as their best response, and the most frequent adverse events of all grades were constipation, diarrhea, nausea, and fatigue.
Book ChapterDOI
Chemotherapy in Advanced Non-Small Cell Lung Cancer. Changes in Performance Status and Tumour-Related Symptoms
TL;DR: Meta-analyses of recent trials reveal a modest survival benefit for combination chemotherapy over best supportive care, although there is no strong evidence from randomized trials for superiority of combination over single-agent therapy.